Table 4.

PASI 75 and PASI 90 responses during the first and third months in patients with a body mass index <30 (normal and overweight) when the biologics were evaluated separately.

Continuous Variables	ADALIMUMAB (N=29)	ETANERCEPT (N=8)	INFLIXIMAB (N=10)	SERTOLIZUMAB PEGOL (N=6)	USTEKINUMAB (N=39)	SECUKINUMAB (N=39)	IXEKIZUMAB (N=12)	RISANKIZUMAB (N=8)	GUSELKUMAB (N=6)	Total biologic (N=157)
Patients who achieved PASI 75 during the first month	48.3% (N=14)	12.5% (N=1)	50% (N=5)	33.3% (N=2)	53.8% (N=21)	52.5% (N=21)	81.8% (N=9)	25% (N=2)	33.3% (N=2)	49.0% (N=77)
Patients who achieved PASI 75 the third month	69.0% (N=20)	37.7% (N=3)	40.0% (N=4)	50.0% (N=3)	76.9% (N=30)	84.5% (N=33)	100% (N=11)	50.0% (N=4)	33.3% (N=2)	70.1% (N=110)
Patients who achieved PASI 90 the first month	31.0% (N=9)	0.0% (N=0)	50.0% (N=5)	0.0% (N=0)	48.7% (N=19)	33.3% (N=13)	45.5% (N=5)	12.5% (N=1)	16.7% (N=1)	33.8% (N=53)
Patients who achieved PASI 75 the third month	58.6% (N=17)	12.5% (N=1)	30.0% (N=3)	33.3% (N=2)	69.2% (N=27)	67.5% (N=27)	100% (N=11)	37.5% (N=3)	16.7% (N=1)	58.6% (N=92)

PASI = Psoriasis Area and Severity Index.